The combination of a small pool of patients at any given time with the availability of many potential neuroprotective agents to be tested in ALS requires efficient phase II trial designs. Objective: To describe the design of the Clinical Trial of High Dose Coenzyme Q10 (CoQ10) in ALS (QALS study)-a phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial. Methods: The study design features two stages. The first stage (dose selection) identifies which of two doses of CoQ10 (1800 mg or 2700 mg) is preferred using a selection procedure rather than a formal hypothesis test. The second stage (early efficacy test) compares the preferred dose of CoQ10 against placebo using a non-superiority or futility design. Data from patients assigned to the preferred dose of CoQ10 in the first stage are also used in the second stage. The primary outcome measure is the decline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRSr) score from baseline to 9 months. Results: The total sample size required is 185 patients, as compared to a much larger sample size estimated to be necessary using a conventional superiority design (total: 852 patients). The authors report a bias correction made necessary by the inclusion of patient data from the first stage in the second stage. Conclusions: Several features of the Clinical Trial of High Dose Coenzyme Q10 in ALS study design promote efficiency. These features may be beneficial in phase II trials in amyotrophic lateral sclerosis and other fields.
its prevalence is limited by relatively short disease duration, typically leading to death within 2 to 4 years of onset.
2, 3 The combination of a small pool of patients at any given time with the current availability of many potential neuroprotective agents to be tested in ALS clinical trials 4 makes it necessary to assess the promise of candidate drugs using efficient phase II trial designs, before moving to large and costly phase III trials.
Most ALS trials to date have employed a two-arm, parallel study design. Few previous reports have explored the properties of alternative clinical trial designs for ALS, including the crossover design 5 and a sequential trial design, which permits early stopping according to prespecified rules. 6 Others have described a two-arm (or multiple-arm) lead-in design, in which patients have their rate of progression measured during an initial period, and are then randomized to receive either placebo or active treatment (or active treatment only for different lengths of time). 7 The only alternative designs specifically proposed for phase II ALS trials involve the use of historical control data, which are obtained either from a natural history database 8, 9 or by using patients who will receive active treatment as their own controls (lead-in natural history controls). 9, 10 We describe an efficient study design that was specifically developed for the Clinical Trial of High Dose Coenzyme Q10 (CoQ10) in ALS (QALS study)-a phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial. The design includes a concurrent control group and utilizes relatively few patients, while it addresses two aims set out by the clinical investigators: 1) to select between two alternative doses of CoQ10 and 2) to conduct an early efficacy test of CoQ10 compared to placebo. Some of the characteristics of the design that make it efficient carry methodologic requirements of their own. Appropriate ways to deal with these were devised and applied in the planning stage of the trial, and are reported here. Study design. The study design features two stages (figure). The first stage (dose selection) identifies which of two doses of CoQ10 (1800 mg or 2700 mg) is preferred using a statistical selection procedure. The second stage (early efficacy test) compares the preferred dose of CoQ10 against placebo and assesses whether there is sufficient early evidence of efficacy to justify continuing this comparison in a full phase III trial. In both stages, the primary outcome measure is the decline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRSr) score from baseline (randomization) to 9 months.
As noted, we identify the preferred dose of CoQ10 by means of a selection procedure rather than a formal hypothesis test. In a selection paradigm, interest is not in guarding against commission of a type I error under the assumption of equal efficacy; rather, interest resides in making a required selection between doses to move forward to efficacy testing. 12, 13 If there were equal efficacy between doses, we would be indifferent to which dose is selected, which is why type I error is unimportant in the selection stage. However, if one dose has superior efficacy compared to the other dose, we can achieve a high probability of correct selection (i.e., the probability that the selection procedure correctly selects the truly superior dose) (see appendix E-1 for selection procedure rules [available on the Neurology Web site at www.neurology.org]).
The dose selected at the conclusion of the first stage is then brought forward to the second stage for the early test of efficacy. In this stage, we consider it most important to control the probability of falsely rejecting the hypothesis that CoQ10 is beneficial for patients with ALS, which would prevent testing this drug in a phase III trial. Thus, the design of this phase II efficacy test is a two-arm non-superiority (or futility) design. The primary null hypothesis is that CoQ10 reduces the mean ALSFRSr decline over 9 months (assumed greater than zero) by at least 20% compared to placebo. It is tested against the non-superiority alternative that CoQ10 reduces the mean ALSFRSr decline over 9 months by less than 20% compared to placebo. We will reject H o if there is significant evidence of non-superiority at the one-sided alpha ϭ 0.10 level. If so, the trial stops for futility. If H o is not rejected, we will conclude that there is inadequate evidence of non-superiority, which, given adequate power, will justify proceeding to a phase III trial. In this context, the power of the efficacy test represents the probability of calling the drug futile given that it reduces the mean ALSFRSr decline by any given percentage less than 20%, or actually increases the mean decline compared to placebo.
Data from patients assigned to the preferred dose of CoQ10 in stage 1 are also used in stage 2 (see figure) . An additional 35 patients are randomized to placebo in stage 1, to provide randomized, concurrent control data that will be included in the stage 2 analysis. After the dose selection in stage 1, 80 more patients are randomized 1:1 to the preferred dose of CoQ10 or placebo. By the end of stage 2, data will be available on 75 patients in each group (35 from stage 1 plus 40 from stage 2) for the early efficacy test comparing the preferred dose of CoQ10 to placebo.
Assessment of reliability of the outcome measure. Since the ALSFRSr is a functional rating scale 14, 15 rather than a clear-cut binary outcome, its use as a primary outcome measure requires assessing its reliability when administered by the evaluators participating in the trial. The inter-rater reliability of the ALSFRSr was assessed during a Coordinators and Evaluators Meeting that took place before trial enrollment started. Nine patients with ALS followed at the Eleanor and Lou Gehrig MDA/ALS Research Center agreed to participate. After an evaluator training session, each patient was rated by a different set of six evaluators who were randomly selected from the 19 clinical site evaluators. The intraclass correlation coefficient was calculated using a one-way random effects analysis of variance. 16 The intra-rater reliability of the ALSFRSr and the reliability of the ALSFRSr administered by telephone will be assessed during the early stages of the trial.
Results. Bias correction. The fact that the stage 2 efficacy test includes data from stage 1 and the "winning" CoQ10 dose in stage 1 is selected specifically because it is associated with the smaller mean ALSFRSr decline introduces a bias into the stage 2 comparison of CoQ10 at the selected dose vs placebo. Specifically, the probability of declaring futility is decreased, because the selection of the CoQ10 dose associated with the smaller mean ALSFRSr decline in stage 1 can capitalize on chance fluctuations. Given this, a compensating bias correction was developed and will be incorporated into the t test comparing the mean ALSFRSr decline over 9 months in the CoQ10 and placebo groups at the end of stage 2. Formulas for the bias correction under two specified scenarios and for the calculation of the appropriate t statistic are presented in appendix E-2. Detailed derivations of these formulas are provided in the technical report E-1.
Sample size calculations. For power and sample size calculations, we estimated the mean ALSFRSr score decline over 9 months using data from a negative ALS clinical trial that employed the original ALSFRS (dataset used with permission). 17 We computed the decline in the ALS-FRS score from baseline to the 9-month visit for each patient. This information was unavailable for 61 of 204 patients due to death before the 9-month visit (16 patients) or missing ALSFRS score at 9 months (45 patients). After imputing the worst possible score at 9 months for patients who died before the 9-month visit, the mean decline in ALSFRS over 9 months in 159 patients was 8.5 (SD 8.4).
Figure. Two-stage phase II design of the Clinical Trial of High Dose Coenzyme Q10 in ALS (QALS study; total: 185 patients, 105 in stage 1 and 80 in stage 2).
The total sample size in our study is 185 patients (see figure) . In the selection procedure, for a probability of correct selection Ն80% when the true absolute difference in mean ALSFRSr decline over 9 months between the two CoQ10 doses is 1.7 (20% of 8.5) points or more, 35 patients per treatment arm are necessary (see appendix E-1 for details). For comparison, suppose that, instead of using the selection procedure, we selected a dose by rejecting the null hypothesis of equal efficacy in a formal hypothesis test with two-sided alpha ϭ 0.10. That would require 304 patients per group for a power of 80% in Student's twosample t test given the same true absolute difference between the two CoQ10 doses as above, and we would still need to decide on a dose if the null hypothesis were not rejected.
The table provides power estimates for the efficacy test in stage 2 according to the relative difference between the CoQ10 and placebo groups. Under scenario (a) (i.e., assuming the true efficacies of the two CoQ10 doses are equal, see appendix E-2), a sample size of 75 per group provides more than 80% power to reject the primary null hypothesis and declare futility of the drug given that the true mean ALSFRSr decline in the preferred dose of CoQ10 is at least 10% higher than in the placebo group. Because the distribution of mean decline in ALSFRSr at the end of stage 2 for the CoQ10 group is not precisely normal due to the selection at stage 1, the distribution of the test statistic t* in appendix E-2 is not precisely Student t. To check on the accuracy of the t distribution approximation, we prepared simulation studies with 100,000 replications each. As shown in the table (last two columns), the approximation is excellent for the relative differences examined.
A conventional superiority trial of the null hypothesis of equal efficacy of a given dose of CoQ10 and placebo against the alternative that CoQ10 at the given dose reduces the mean ALSFRSr decline over 9 months by 20% compared to placebo (at alpha ϭ 0.10, one-sided) would require 221 patients per group for a power of 80%. Therefore, if one were to first test to select the superior dose as above, which would require 304 patients per group (608 patients for two arms), and follow that with a conventional superiority test, which would require an additional 221 patients per group (442 patients for two arms), a total of 1,050 patients would be required. If instead a one-way analysis of variance were used to test the null hypothesis of equal efficacy in all three treatment arms, 284 patients per group, or 852 patients in total, would be required for power of 80% at the alternative hypothesis effect size of 1.7/8.4 ϭ 0.202 for each of the two doses of CoQ10 compared to placebo.
Reliability of the ALSFRSr. Nine patients participated in the inter-rater reliability assessment (mean age 53.2 years, SD 7.3, median 50, range 44 to 66; four men, five women). The number of evaluators was 19 and the total number of ratings was 54 (six per patient). The intraclass correlation coefficient was 0.93 (95% CI: 0.84 to 0.98), indicating excellent reliability.
Discussion. Three characteristics of the proposed phase II ALS trial design contribute to its efficiency in terms of reducing sample size: 1) the use of a selection paradigm rather than a formal hypothesis test paradigm for the dose selection; 2) the nonsuperiority or futility design in the early efficacy test; and 3) data used for dose selection are also used in the efficacy test. The use of the ALSFRSr as the primary outcome measure instead of mortality further increases the efficiency of the study design by reducing follow-up time. The ALSFRSr has been validated as a predictor of survival time in an ALS trial 15 and in a clinic population. 18 Replacing the fixed-sample size selection procedure with a sequential selection procedure might further reduce the sample size. In a sequential selection procedure, analyses are conducted repeatedly as new data become available until a selection criterion is met. 19 However, given the 9-month follow-up period, a continuous monitoring scheme would leave a potentially large number of randomized patients with incomplete follow-up at the moment of dose selection, and the data from patients randomized to the , the non-centrality parameter of Student t distribution for the bias-corrected two-sample t test under scenario (a) (see appendix E-2). ‡ Based on 100,000 replications each.
ALSFRSr ϭ ALS Functional Rating Scale-revised.
non-selected dose of CoQ10 would not be used in any analysis, which was considered inappropriate by the investigators. A futility design utilizing historical control data is currently being used in a NINDS-sponsored program to identify neuroprotective treatments for Parkinson disease. 20 In addition, the application of the singlearm phase II futility study design to stroke trials has been recently discussed. 21, 22 This allows even smaller sample sizes, but raises issues of validity that typically attend historical control studies. While the use of historical controls in phase II ALS trials has been considered by the ALS research community, [23] [24] [25] [26] a consensus viewpoint on ALS trial design states, "It is not appropriate to use historical controls for comparisons, due to a large degree of variability in disease course and evolving standards of patient care." 27 Our study has the benefit of a concurrent placebo control group. Assuming an acceptable safety profile for the preferred dose of CoQ10, we require evidence not inconsistent with at least a 20% reduction in the mean ALSFRSr decline over 9 months for CoQ10 compared to placebo. This definition of "superiority" is based on clinical judgment as to where an important benefit to patients with ALS begins.
The power to reject the null hypothesis of 20% superiority of CoQ10 is only slightly better than 50% when the CoQ10 and placebo efficacies are equal (see table) . This was deemed acceptable given the goal of this phase II trial, which is to allow a possibly superior drug that has not been tested in large samples to enter a definitive phase III testing, even if its early efficacy is not clear. By placing the burden of proof on futility, we are able to limit the rate of the more serious error of stopping a truly superior drug from proceeding to phase III testing. A further limitation is that we estimated the mean and SD for decline in ALSFRSr over 9 months by using data from a previous trial that employed the original (non-revised) ALSFRS. 17 Because the range in the ALSFRSr is higher than in the ALSFRS (48 vs 40 points), using ALSFRS data may have led to an underestimation of the true SD for decline in ALSFRSr over 9 months. A higher SD of the primary outcome measure would reduce the actual power of our study. However, the ALSFRS was not a primary outcome measure in this previous trial, 17 and this may have increased its SD due to less than optimal reliability. The variability of the ALSFRSr in our trial will be minimized by the training and assessment efforts undertaken to obtain high inter-and intrarater reliability.
Although the design described here was specifically developed for a phase II clinical trial of CoQ10, the features that ensure its efficiency can be beneficial in other ALS trials. A selection procedure can be used for selecting not only among different doses of the same drug, but also among different candidate drugs. Moreover, the use of a futility design for the early assessment of drug efficacy compared to placebo can prevent further investigation of an unpromising drug in a full phase III study. These design features can accelerate progress in the search for an effective therapy for ALS by sparing and redirecting limited available resources. They can also be useful in other clinical fields where similar challenges are faced.
